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Neuroprotective efficacy of P7C3
compounds in primate hippocampus
Melissa D. Bauman1,2,3,4, Cynthia M. Schumann1,2, Erin L. Carlson1, Sandra L. Taylor4, Edwin Vázquez-Rosa5,
Coral J. Cintrón-Pérez5, Min-Kyoo Shin5, Noelle S. Williams6 and Andrew A. Pieper5
Abstract
There is a critical need for translating basic science discoveries into new therapeutics for patients suffering from
difficult to treat neuropsychiatric and neurodegenerative conditions. Previously, a target-agnostic in vivo screen in
mice identified P7C3 aminopropyl carbazole as capable of enhancing the net magnitude of postnatal neurogenesis by
protecting young neurons from death. Subsequently, neuroprotective efficacy of P7C3 compounds in a broad
spectrum of preclinical rodent models has also been observed. An important next step in translating this work to
patients is to determine whether P7C3 compounds exhibit similar efficacy in primates. Adult male rhesus monkeys
received daily oral P7C3-A20 or vehicle for 38 weeks. During weeks 2–11, monkeys received weekly injection of 5′-
bromo-2-deoxyuridine (BrdU) to label newborn cells, the majority of which would normally die over the following
27 weeks. BrdU+ cells were quantified using unbiased stereology. Separately in mice, the proneurogenic efficacy of
P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major
depression. Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the
survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. In
mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal
neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. This
pilot study provides evidence that P7C3-A20 safely protects neurons in nonhuman primates, suggesting that the
neuroprotective efficacy of P7C3 compounds is likely to translate to humans as well.
Introduction
Novel therapeutics are severely lacking for patients
suffering from neuropsychiatric and neurodegenerative
diseases1–4. One promising avenue for central nervous
system (CNS) drug development is to address alterations
in the magnitude of postnatal hippocampal neurogenesis
and hippocampal volume reported for many CNS dis-
orders, including Alzheimer’s disease, schizophrenia,
major depression, addiction and anxiety5,6. Although
questions have recently been raised regarding the extent
of adult human hippocampal neurogenesis7,8, converging
evidence from human and animal studies suggests that
the ability to augment the net magnitude of postnatal
neurogenesis may present a potential therapeutic inter-
vention for multiple RDoC domains inclusive of symp-
toms associated with depressive and bipolar disorders, as
well as for general conditions of impaired cognition9–15. A
rigorous preclinical research pipeline is needed to trans-
late promising pharmacological interventions identified in
animal model systems into new therapeutic
interventions16.
Here we present a novel, cross-species approach to
advancing preclinical evaluation of the aminopropyl car-
bazole compound P7C3-A20 from rodents to nonhuman
primates. In rodents, the P7C3-series of compounds
enhances neuronal survival under conditions that would
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normally lead to cell death3. The prototypical P7C3
molecule was first discovered through an unbiased in vivo
screen for drug-like molecules capable of safely enhancing
the net magnitude of postnatal hippocampal neurogenesis
in mice17. The third compound (C3) of the seventh pool
(P7), thereby named P7C3, was discovered to have this
ability by virtue of protecting young hippocampal neurons
from dying, without affecting their rate of proliferation in
the postnatal hippocampus. Aged rats that underwent
prolonged administration of P7C3 also performed better
on cognitive tasks and exhibited decreased cell death in
the hippocampus17. Subsequently, the neuroprotective
effects of P7C3 and its derivative compounds have been
further demonstrated in broad preclinical rodent models
of CNS disease and injury, including environmental
stress-related hippocampal cell death18–20, amyotrophic
lateral sclerosis21, Parkinson’s disease22–25, traumatic
brain injury26–28, peripheral nerve crush29,
chemotherapy-induced peripheral neuropathy30, optic
nerve injury31,32, Alzheimer’s disease33, stroke34–36, and
recently expanded to acetaminophen-induced liver toxi-
city37. Mechanistically, P7C3 increases nicotinamide
adenine dinucleotide (NAD) flux in mammalian cells
under conditions of otherwise overwhelming energy crisis
that would normally lead to cell death38.
While preclinical rodent models have laid the founda-
tion for our understanding of the neuroprotective efficacy
of P7C3 compounds, there are limitations in relying solely
on rodent models to develop novel therapeutics for
complex CNS diseases in humans39. Moreover, comple-
tion of all stages of adult hippocampal neurogenesis (i.e.,
proliferation, differentiation, survival, and integration)
takes several weeks in rodents40, but requires months
longer in both human41 and nonhuman primates42.
Therefore, preclinical evaluation of drugs targeting hip-
pocampal neurogenesis may benefit from experiments in
animals more closely related to humans, such as the
rhesus macaque monkey (Macaca mulatta). Rhesus
monkeys are genetically and physiologically similar to
humans, and are the most widely used nonhuman primate
in biomedical research43. Moreover, the complex neu-
roanatomy and behavioral repertoire of the rhesus mon-
key provides a powerful preclinical platform to evaluate
promising CNS therapeutic agents44,45. As an initial step
in establishing a robust nonhuman primate model, we
first evaluated the neuroprotective efficacy of prolonged
(38 week) oral administration of P7C3-A20, one of the
most highly-potent compounds in the
P7C3 series20,21,23,26,35, on hippocampal neurogenesis in
adult, male rhesus monkeys. Monkeys from P7C3-A20
treatment and vehicle control groups received weekly
injections of the thymidine analog cell-division marker,
5′-bromo-2-deoxyuridine (BrdU) during weeks 2–11 of
compound exposure, followed by an extended period of
27 weeks of either P7C3-A20 or vehicle administration. In
parallel, we also executed a study in mice to directly
compare the proneurogenic efficacy of P7C3-A20 to that
of NSI-189, a proneurogenic drug currently in clinical
trials for patients with major depression. Here we present
our initial findings using this integrated in vivo mouse-to-
monkey evaluation of P7C3 compounds.
Materials and methods
Methods for the nonhuman primate and rodent studies
are summarized briefly below and described in detail in
the supplemental material.
Nonhuman primate studies
Animal selection
Experimental procedures were developed in consulta-
tion with the veterinary staff at the California National
Primate Research Center and performed in accordance
with the University of California, Davis Institutional
Animal Care and Use Committee. Eight adult male rhesus
monkeys (Macaca mulatta) were randomly assigned to
one of two treatment groups: (i) Treatment with P7C3-
A20 or (ii) Vehicle controls (Table 1). While this is
modest sample size for a pilot study, a target sample size
of N= 4 per group is not uncommon in nonhuman pri-
mate research46,47. Moreover, previous P7C3A20 data in
rodent models demonstrated sufficiently low variability to
achieve statistical significance with groups of this size.
Unfortunately, one of the vehicle control animals was
flagged by veterinary staff for health related concerns and
was removed from plans for BrdU quantification resulting
in a final sample of N= 4 P7C3A20 treated and N= 3
vehicle control.
P7C3-A20 formulation and treatment
P7C3-A20 was synthesized under GLP conditions by
Southwest Research Institute as further described in
supplemental material. Daily oral administration of
compound (10 mg/kg, 0.5 ml/kg) or vehicle control
(0.5 ml/kg) was implemented at 9 am (+/−30min) for
266 consecutive days (38 weeks) by experienced animal
care technicians (Fig. 1). General health and appetite were
monitored daily by trained technicians and/or veterinary
staff.
Table 1 Experimental groups
Treatment Age (years) Weight (kg)
P7C3-A20 (N= 4) 5.71 11.56
Vehicle (N= 4)a 5.98 11.91
aOne vehicle treated control was removed from BrdU quantification for
unrelated medical issues, but data was included for pharmacokinetic analyses
and tissue toxicity studies
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BrdU injections
Each monkey received weekly injections of the thymi-
dine analog cell-division marker, 5′-bromo-2-deoxyur-
idine (BrdU; Boehringer Mannheim, 150 mg/kg i.v.) on
treatment Day 9, 16, 23, 30, 37, 44, 51, 58, 65, and 72
between 1 and 3 pm in the afternoon. The dose of BrdU
was selected in order to maximize the amount of labeling,
while minimizing the possible toxic side-effects of the
marker48. The final BrdU injection on Day 72 occurred
194 days (27 weeks) prior to euthanasia. Previous groups
have utilized an interval of 2.5 months between BrdU
injection and euthanasia to allow sufficient time for
nonhuman primate cells to mature49. However, more
recent evidence indicates that granule cell maturation in
the nonhuman primate is protracted over a minimum
6 month time period42. For this reason, we extended the
time between the final BrdU injection (day 72) and
euthanasia (day 266) to 6.5 months50,51.
Pharmacokinetic analysis
Collection of baseline (pre-treatment) and monthly
blood samples are described in supplemental materials and
Fig. 1. Blood samples were processed for plasma (PK
samples) or both plasma and serum (Monthly samples).
CBC/CHEM panels were run on Day 0 (pre-treatment),
Day 7 and at each monthly blood sample. Detection of
P7C3-A20 in plasma of monkeys was conducted by Abbvie
Pharmaceuticals (North Chicago, IL, USA) following a
protocol previously developed for evaluation of P7C3-A20
in rodent samples)27. Compound extraction of plasma
samples is further detailed in supplemental materials.
Histology and stereological analyses
Brain collection and processing from monkey followed
previously established protocols52,53 and is described in
further detail in supplemental material. Following perfu-
sion, brains were extracted, placed in refrigerated paraf-
ormaldehyde, cryoprotected, and frozen in isopentane.
Additional tissues, as described in supplemental materials,
were collected and processed for toxicology assessment.
The brain was cut into coronal sections with a freezing
microtome into six 30μm series and one series at 60 μm
(Microm HM 450). Every fourth section of one of the
30μm series (~15 sections evenly-spaced every 960 μm
throughout the entire rostrocaudal extent of the hippo-
campus) was processed with BrdU immunohistochem-
istry. Additional sections adjacent to the BrdU
immunostained sections were stained with a thionin-
based Nissl protocol for anatomical reference as pre-
viously described52. An investigator blind to the treatment
status of each specimen performed all analyses, as
described below.
The granule cell layer of the dentate gyrus of the hip-
pocampus in both right and left hemispheres was deli-
neated according to previously published
cytoarchitectonic descriptions54–56. Contours were drawn
on each 30 μm BrdU immunostained section (evenly
spaced every 960 μm throughout the entire rostrocaudal
extent of the hippocampus) and verified with the nissl-
stained section contours to provide a consistent boundary
for counting the number of BrdU+ cells within the
granule cell layer. All measurements were made using
Stereoinvestigator software (MBF Bioscience, Williston,
VT) on a Zeiss Axio Imager.Z2 Vario microscope with
automated stage controller (Ludl Mac6000) and Hei-
denhan length gage for z-axis (section thickness) mea-
surement. Volume measurements were measured
according to the Cavalieri principle57. The stereological
method optical fractionator (counting frame: 1 µm, guard
zone: 2 µm) was used to estimate the number of BrdU+
cells. BrduU+ cells were not counted if they came into
focus outside of the counting frame (i.e., in the guard
zone). The stereological method applied in this study
adhered to the sampling scheme specifically described in
West58, as follows: Given the low number of BrdU+ cells
present within the counting frame, the entire area of the
section for the disector was used to count all BrdU+ cells
that fell within the counting frame (area sampling fraction
[asf]= 1) and multiplied by the inverse of the section
sampling fraction to obtain estimates of the total number
of BrdU+ cells in the granule cell layer58.
Statistics
We compared mean cell counts between monkeys
treated with P7C3-A20 using a two-sample t-statistic
assuming unequal variances. One animal had a large cell
count resulting in a skewed distribution. We therefore
used a complete permutation null distribution to
Fig. 1 Experimental timeline
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determine the significance level, because it does not
require assuming the data were drawn from a normally-
distributed population. In small samples such as repre-
sented in this study, the sample mean can be strongly
impacted by very high or low values. Because of the
relatively large cell counts for one animal in the inter-
vention group, we also conducted a Wilcoxon rank sum
test to compare distributions between the two groups. An
exact p-value was calculated for this test. All tests were
two-sided.
Rodent studies
All rodent animal procedures were performed in
accordance with the University of Iowa animal care
committee’s regulations. Animals were housed in
temperature-controlled conditions, provided food and
water ad libitum, and maintained on a 12 h light/dark
cycle (7:00 am–7:00 pm). Male C57BL/6 J mice were
purchased from The Jackson Laboratory. Experiments
designed to compare P7C3-A20 to NSI-189 for ability to
increase the net magnitude of hippocampal neurogenesis
using a standard 5 day in vivo assay were followed by
targeted assays of proliferation and survival and newborn
hippocampal neurons in the mouse dentate gyrus
(described in supplemental material). General health and
appearance of all animals was monitored daily by trained
technician and veterinary staff, and no abnormalities were
noted during this brief treatment period. After 5 days of
daily BrdU (Sigma-Aldrich) administration at 9:00 am,
mouse brains were collected and prepared as described in
supplemental materials. The number of BrdU+ cells in
the entire dentate gyrus subgranular zone (SGZ) was
quantified per our established procedures17,19,20,23,24,59.
Briefly, BrdU+ cells are manually counted under 20×
magnification within the SGZ and dentate gyrus in every
fifth section throughout the entire hippocampus. Then a
picture of the dentate gyrus field is obtained at 4X mag-
nification, and the volume of the dentate gyrus granular
cell layer is determined by using NIH Image J software
tailored to the microscope to trace the area, and then
multiplying by the thickness of the section. All data were
normally distributed; therefore, in instances of multiple
mean comparisons, analysis of variance was used, fol-
lowed by post hoc comparison using Tukey’s method. In
instances of direct comparison, two-tailed Student’s t-test
was performed. Alpha levels were set to .05, and analyses
were conducted using GraphPad Prism (GraphPad Soft-
ware, Inc., La Jolla, CA). The presence our outliers was
tested using ROUT method in Prism and defined as
having Q= 0.1%. In this study, no outliers were detected.
Significance is denoted as *p= .05, **p= .01, ***p= .001,
****p= .0001, and not significant. A blinded examiner
conducted all analyses, and code was not broken until
analyses were completed.
Results
38 Weeks of daily oral dosing (10mg/kg) of P7C3-A20
provides sustained plasma exposure in nonhuman
primates
Orally-administered P7C3-A20 provided sustained
plasma exposure in rhesus monkeys (Fig. 2). To ensure
good compliance for compound administration, a for-
mulation of corn oil and flavored syrup was utilized for
oral dosing in the monkeys. Prior to initiation of the
primate study, this formulation was evaluated in male
Fisher 344 rats to ensure comparable exposures with the
rodent DMSO/cremophor formulation previously uti-
lized21,23. Exposures were found to be comparable for a
10mg/kg dose administered by oral gavage (DMSO/
Cremophor: AUC 12958 h*ng/ml, Cmax: 928 ng/ml; Oil/
Syrup: AUC 15174 h*ng/ml, Cmax 1155 ng/ml). Drug
levels were evaluated over a 24 h period on Day 1, 7, and
266. Overall exposure, defined as area under the curve
Mean (±SEM) Plasma Concentraons of P7C3-A20
following 10 mg/kg/day Oral Dosing
A P7C3-A20 compound levels evaluated
over a 24 hour period on Day 266
B Monthly P7C3-A20 compound levels
Fig. 2 a P7C3-A20 compound levels were evaluated over a 24 h
period on Days 1, 7, and 266, and the overall exposure measured
(area under the curve: AUC) differed by no more than two-fold.
Compound levels varied from an average Cmax of 963 to 2320 ng/ml
at around 4 h to a trough of 73–132 ng/ml at 24 h immediately prior
to the next dose. Individual animal data from day 266 are presented in
a. b P7C3-A20 levels were also measured once a month, 6 h after
dosing, a time point close to the estimated maximal concentration
point
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(AUC), differed by no more than two-fold. Compound
levels varied from an average Cmax of 963–2320 ng/ml at
around 4 h, to a trough of 73–132 ng/ml at 24 h just prior
to the next dose, as presented at day 266 (Fig. 2a). P7C3-
A20 levels were also measured once a month, 6 h after
dosing, a timepoint close to the estimated maximal con-
centration point. Here again, levels were fairly consistent
and showed no trend towards increase or decrease, sup-
porting the favorable chemical property of lack of
induction or inhibition of any clearance mechanisms,
such as cytochrome P450-mediated metabolism (Fig. 2b).
Finally, although this represents a small cohort of animals,
there was little variability between animals, indicating that
consistent and fairly equivalent exposures were achieved
in each non-human primate.
Chronic P7C3-A20 ingestion is not associated with toxicity
in nonhuman primates
After 38 weeks of daily oral exposure at 10 mg/kg dose
of P7C3-A20, tissues were comprehensively collected at
necropsy and evaluated by a pathologist blind to experi-
mental condition. No microscopic evidence of toxicology
was detected in any of the tissues examined, including
eyes, lung, heart, aorta, tongue, spleen, liver, kidney,
adrenal, thyroid, parathyroid, pancreas, stomach, testes,
small intestine, large intestine, skeletal muscle, vesicular
gland, spinal cord, peripheral nerve, prostate, salivary
glands, gall bladder, bone marrow, epididymis, optic
nerve, lymph nodes, mammary gland, larynx, skin, tra-
chea, ureter, bone, joint, and pituitary gland. This com-
plete lack of toxicity after daily oral administration of
P7C3-A20 for 38 weeks to non-human primates is a
favorable indication for the translational potential of the
P7C3-series into a safe treatment for patients.
Orally-administered P7C3-A20 elevates survival of
newborn hippocampal neurons in nonhuman primates:
Survival of young hippocampal neurons was examined
27 weeks after the final injection of the cell-division
marker BrdU (Fig. 3a–c; Table 2). The mean number of
BrdU+ cells differed significantly (t=−2.30, df= 3.31, p
= 0.029 based on permutation null distribution) between
monkeys treated with P7C3-A20 (mean= 3275, SD=
1847) and those that received the vehicle control (mean=
1095, SD= 368) (Fig. 3d). Although the Wilcoxon test
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Fig. 3 a Approximately 15 sections per animal evenly spaced 960 μm apart covering the rostral to caudal extent of the hippocampus were
used to estimate the number of BrdU-labeled cells. b Contours were outlined on Nissl-stained sections for anatomical reference. c Contours were
drawn on BrdU immunohistochemically stained sections to measure volume and count the number of BrdU-labeled cells within the granule cell
layer. d The total number of BrdU positive cells (left and right hemispheres) differed significantly (p= 0.029) between monkeys treated with P7C3A20
(mean= 3275, SD= 1847) and those that received the vehicle control (mean= 1095, SD= 368). However, median values fell just shy of the set
significance value at 0.05 level (p= 0.056). e As predicted, the groups did not differ in bilateral GCL volume (p= 0.857) as a function of P7C3-A20
exposure
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comparing the two distributions fell just short of statis-
tical significance based on a 0.05 threshold (W= 0, p=
0.057), all treated animals had higher numbers of BrdU+
cells than animals in the control group, as shown in
(Supplemental Fig. 1). Animals were randomly assigned to
treatment group in order to best control for the possibility
of inter-animal variation in baseline postnatal neurogen-
esis, and did not differ in bilateral GCL volume (p=
0.857) as a function of P7C3-A20 exposure (Fig. 3e).
Although BrdU can also label DNA repair events, this is
unlikely to be a factor in our study that showed a differ-
ence between P7C3-A20 and vehicle groups, as P7C3
compounds have an extensive record of safety in pub-
lished preclinical models and we also saw no evidence of
toxicity anywhere in the body associated with P7C3-A20
administration.
P7C3-A20 is more efficacious and mechanistically distinct
in mice from the proneurogenic drug NSI-189
We next compared in mice the efficacy of P7C3-A20 to
that of NSI-189, an experimental proneurogenic drug that
acts by unknown mechanisms to enhance hippocampal
neurogenesis. To date, NSI-189 has shown protective
efficacy in a rat model of stroke60, as well as a promising
effect in a phase1B randomized double-blinded placebo-
controlled multiple dose-escalation study in adult patients
with major depressive disorder61. We first compared
P7C3-A20 to NSI-189 for the ability to increase the net
magnitude of hippocampal neurogenesis in a standard
5 day in vivo assay of BrdU-labeled cells in the dentate
gyrus17. Here, mice were socially isolated without any
environmental enrichment for 2 weeks, per our standard
protocol, and then subjected to daily administration of
both the test proneurogenic compound and a daily dose of
BrdU (50 mg/kg ip). In this experiment, NSI-189 showed
a nonsignificant dose-dependent increase in the number
of BrdU+ cells, whereas P7C3-A20 showed a statistically
significant (p < .01) increase in the number of BrdU+ cells
compared to vehicle-treated animals (Fig. 4).
The standard 5 day assay captures agents that increase
the net magnitude of hippocampal neurogenesis, without
distinguishing whether they act by enhancing prolifera-
tion or promoting survival. For example, this assay was
originally used to discover the prototypical P7C3 mole-
cule17, which was subsequently shown to elevate hippo-
campal neurogenesis by selectively blocking neuronal
death with affecting proliferation of neural precursor cells.
Thus, we compared P7C3-A20 to NSI-189 in standard
assays of proliferation (1 h after BrdU administration) and
survival (15 days after BrdU administration) (Fig. 5).
Table 2 Summary of average number BrdU positive cell
counts and GCL volumes [Mean (±SEM)]
BrdU positive cells GCL volume (mm³)
Left
hemisphere
Right
hemisphere
Left
hemisphere
Right
hemisphere
Vehicle 597 (±115) 498 (±116) 10.7 (±0.2) 11.4 (±1.3)
P7C3-
A20
treated
1495 (±514) 1781 (±409) 10.1 (±0.8) 11.3 (±0.5)
1 mm 
Vehicle
1 mm 1 mm 
1 mm 
1 mm 
NSI-189 (10 mg/kg/day)
P7C3-A20 (10 mg/kg/day)
NSI-189 (3 mg/kg/day)
NSI-189 (1 mg/kg/day)
Fig. 4 Compounds were administered intraperitoneally at the daily dose indicated for 5 days, during which time mice were also dosed
intraperitoneally daily with BrdU (50mg kg-1day-1) to label newborn hippocampal neurons. Representative micrographs are shown on the
left, with quantified data on the right represented as mean +/- standard error of the mean (SEM). NSI-189-treated mice showed a nonsignificant
increase in the number of BrdU+ cells that was statistically not different from vehicle. P7C3-A20-treated mice showed a statistically significant (p
< .01) increase in the number of BrdU+ cells compared to vehicle-treated animals
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Proliferation was assayed by measuring the number of
BrdU+ cells/mm3 dentate gyrus 1 h after a pulse of BrdU
(150mg/kg ip) in animals that had already received 3 days
of daily P7C3-A20 (10 mg/kg/day ip) or NSI-189 (10 mg/
kg/day ip). Here, P7C3-A20 elicited no increase in cellular
proliferation, compatible with our previous observations,
while treatment with NSI-189 elevated proliferation of
neural precursor cells by approximately 70%. Next, to
assay the neuroprotective efficacy for young hippocampal
neurons, we measured the number of BrdU+ cells/mm3
dentate gyrus 15 days after a pulse of BrdU (150mg/kg ip)
in animals that received daily treatment with either P7C3-
A20 (10 mg/kg/day ip) or NSI-189 (10 mg/kg/day ip)
starting at the time of delivery of the BrdU pulse. Here,
animals treated with P7C3-A20 showed a survival rate
approximately three times greater than vehicle-treated
animals, with migration of some cells out of the sub-
granular zone and into the dentate gyrus (Fig. 5). Animals
treated with NSI-189, however, showed only a minor and
non-significant trend towards increased survival, indicat-
ing that the proneurogenic efficacy of NSI-189 is likely
confined to its pro-proliferative cellular effect. These
experiments show that P7C3 compounds increase the net
magnitude of hippocampal neurogenesis to a greater
extent than NSI-189 by virtue of the ability of P7C3
compounds to protect neurons from cell death.
Discussion
P7C3 compounds were first identified through an
unbiased screen of hippocampal neurogenesis in
rodents17, and subsequently shown to have neuroprotec-
tive properties for a number of CNS relevant rodent
models18–35. Here we establish the next step in advancing
P7C3 along the translational pipeline into a species more
closely related to humans—the rhesus macaque. This
study provides two major, novel findings. First, we
demonstrate that orally-administered P7C3-A20 provides
sustained plasma exposure, is well-tolerated, and protects
young hippocampal neurons in the adult male rhesus
macaque. A higher number of BrdU+ cells in the dentate
gyrus were detected in monkeys treated daily with P7C3-
A20 compared to vehicle (Fig. 3). Second, in a direct
comparison in mice treated with P7C3-A20 compared to
the drug NSI-189 that is currently in clinical trials for
patients with major depression, the survival-promoting
effect of P7C3-A20 appears to augment the net magnitude
of hippocampal neurogenesis more effectively than the
pro-proliferative effect of NSI-189 (Figs. 4, 5). The present
studies add to a growing body of evidence suggesting that
P7C3 compounds offer a promising therapeutic inter-
vention for a number of CNS disorders. Mechanistically,
we have shown in rodent models an cellular systems that
P7C3 increases neuronal NAD flux under conditions that
would normally lead to cell death38, and efficacy of P7C3
compounds in the nonhuman primate suggests that this
general mechanisms of neuronal protection is likely to be
operational in humans as well.
Our initial efforts in the nonhuman primate model
focus on the neuroprotective properties of P7C3 com-
pounds related to adult neurogenesis in the primate
Vehicle
Pr
ol
ife
ra
o
n
Su
rv
iv
al
P7C3-A20 NSI-189
1 mm 1 mm 1 mm 
1 mm 1 mm 1 mm 
Fig. 5 Efficacy on enhancing proliferation of hippocampal neural
precursor cells and survival of young hippocampal neurons was
compared between NSI-189 and P7C3-A20 at a dose of 10mg
kg−1day−1 administered intraperitoneally. Representative
micrographs of BrdU+ cells in the dentate gyrus are shown above,
with quantified data displayed below as mean +/- standard error of
the mean (SEM). Proliferation was assayed in animals that had
received 3 days of daily P7C3-A20 or NSI-189, followed by a 1 h pulse
of of BrdU (150mg/kg ip) P7C3-A20 elicited no increase in cellular
proliferation compared to the level seen in vehicle-treated animals.
NSI-189 elevated proliferation of neural precursor cells by
approximately 70% relative to vehicle (p < .001) and P7C3-A20-treated
mice (p < 0.01). Neuroprotective efficacy for young hippocampal
neurons was assayed in animals that received the same pulse of BrdU
at the same time as initiation of 15 days of daily treatment with P7C3-
A20 or NSI-189. P7C3-A20-treated animals showed a survival rate
approximately three times greater than vehicle-treated (p < .0001) and
NSI-189-treated (p < .001) animals, with migration of some cells out of
the subgranular zone and into the dentate gyrus. Animals treated with
NSI-189 showed a minor and non-significant trend towards increased
survival, indicating that the proneurogenic efficacy of NSI-189 is likely
confined to its pro-proliferative effect on cells. P7C3 compounds
increase the net magnitude of hippocampal neurogenesis to a greater
extent than NSI-189 by virtue of the unique ability of P7C3
compounds to protect neurons from cell death
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hippocampus. As first described in rodents62, neurons
born in the subgranular zone (SGZ) migrate and integrate
into the granule cell layer50,51,63, a process that takes
months longer in nonhuman primates42 and humans41
than in rodents. Hippocampal neurogenesis peaks at
3 months of age for macaques and remains at an inter-
mediate level between 3 months and at least 1 year of age
(roughly equivalent to early childhood)49. Adult macaques
and humans demonstrate persistent levels of neurogenesis
in adulthood49,64, though the number of surviving new-
born neurons decreases substantially with age65. Studies
from rodent models indicate that adult-born neurons
demonstrate a transient period of excitability and plasti-
city thought to recapitulate the early stages of fetal and
postnatal brain development66,67. These properties sug-
gest that adult-born cells may be uniquely positioned to
impact hippocampal activity, in spite of their relatively
low abundance40. Thus, adult-born neurons are thought
to enhance function of hippocampal networks68,69,
though there is no consensus on exact functional con-
tributions. Although new neurons are generated in the
adult human dentate gyrus (DG) of the hippocampus8,63,
the extent to which human hippocampal neurogenesis
persists in aging has been debated7. While additional
research in this fascinating field is clearly warranted, we
also stress that P7C3 compounds are proneurogenic by
virtue of the fact that their neuroprotective efficacy
encompasses both mature and newborn neurons. A
compound that protects against neuronal loss is poten-
tially more attractive for clinical development than one
that exclusively targets proliferation of newborn neurons
in the brain, as a broad and critical role of neuronal loss
has been firmly established in a wide variety of neurolo-
gical and neuropsychiatric conditions.
Dysregulated hippocampal neurogenesis has been
linked to a number of neuropsychiatric diseases, including
major depressive disorder, bipolar disorder, schizophrenia
and anxiety70–76. The ability to regulate adult hippo-
campal neurogenesis may thus provide a route to develop
novel treatments for human neuropsychiatric disease77, as
evidenced by the links between behavioral effects of
antidepressants and stimulation of hippocampal neuro-
genesis in preclinical78,79 and clinical studies80–82. The
current findings support further investigation of the
neuroprotective effects of P7C3 compounds in nonhuman
primate models of impaired cognition83–85 or stress-
related behaviors86,87. P7C3 compounds have also
demonstrated neuroprotective properties in rodent
models of nervous system disease and injury that involve
neurodegeneration outside of the hippocampus (i.e.,
amyotrophic lateral sclerosis, Alzheimer’s disease, Par-
kinson’s disease, traumatic brain injury, stroke, and
chemotherapy-induced peripheral neuropathy). Given
that nonhuman primate models exist for these disorders,
we are now positioned to explore the therapeutic poten-
tial of the P7C3 class of molecules in sophisticated non-
human primate disease models. In future studies with
larger number of animals we will also incorporate analysis
of brain levels of P7C3 compounds as well, in addition to
blood. This integrated in vivo mouse-to-monkey evalua-
tion of neuroprotective compounds may provide impor-
tant benchmarks for utilizing cross-species animal models
and accelerate drug discovery efforts.
In order to assess the survival-promoting effect of
P7C3-A20 relative to the drug NSI-189 currently in
clinical trials for major depression, we also carried out a
direct comparison in mice and found that P7C3-A20
augmented the net magnitude of hippocampal neuro-
genesis more effectively than NSI-189. That NSI-189
promoted proliferation but failed to show a sustained
increase in net magnitude of hippocampal neurogenesis
15 days later suggests that a brief increase in proliferation
does not elicit sustained improvement in hippocampal
function. However, it is unknown whether prolonged
chronic administration of NSI-189 might eventually
achieve this objective through chronic elevation of the
rate of proliferation of hippocampal neural precursor
cells. We have previously shown that P7C3-A20 exerts
potent antidepressant efficacy in a rodent model of
chronic social defeat stress20 in a manner specifically
linked to its ability to increase the net magnitude of
hippocampal neurogenesis by virtue of its survival-
promoting mode of action, and NSI-189 has shown pro-
mising results in a phase1B randomized double-blinded
placebo controlled multiple dose-escalation study in
adults with major depressive disorder61. Inasmuch as
augmenting hippocampal neurogenesis can be assumed to
represent a novel route to treating patients with depres-
sion76,88, our results of greater potency and efficacy of
P7C3 compounds suggest that a drug to emerge from the
P7C3 class of neuroprotective molecules might have
superior efficacy to NSI-189. In addition, concurrent
administration of P7C3 compounds and pro-proliferative
compounds like NSI-189 might have a synergistic effect in
enhancing hippocampal neurogenesis and treating
depression or hippocampal-related cognitive dysfunction
in patients suffering from a spectrum of neurodegenera-
tive conditions related to injury, disease, or normal aging.
Collectively, these studies suggest that the neuropro-
tective property of P7C3 compounds may have broad
applicability for a number of human CNS disorders. The
primary limitation of the current study is the small sample
size of adult nonhuman primates. However, small sample
sizes are not uncommon for initial pilot studies in non-
human primates46,47. Given that early translational studies
tend to have quite high per-subject costs, initial nonhu-
man primate studies must balance the potential infor-
mation gained versus ethical and financial factors89.
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Moreover, the current nonhuman primate study included
only male subjects. In rodent preclinical models of disease
in which P7C3 compounds have been previously applied,
efficacy has correlated with incorporation of surviving and
mature neurons into appropriate circuitry of the brain
related to behavioral outcome in both males and females.
Despite these limitations, this initial nonhuman primate
study has generated preliminary data that support further
evaluation of P7C3-A20 compounds as a promising
treatment for human CNS diseases. In future studies, we
will seek to replicate the nonhuman primate findings in a
larger sample and also determine whether P7C3 com-
pounds have efficacy in female nonhuman primates. We
will also explore hippocampal asymmetry, given that right
and left hippocampal volumes differ in the healthy human
brain90,91 and in CNS diseases92,93. In addition, we will
pursue more sophisticated physiologic analysis of neuro-
nal survival and incorporation into brain circuitry related
to behavioral outcome measures, such as cognitive and
mood-like behaviors, and explore the therapeutic poten-
tial of the P7C3 class of molecules in sophisticated non-
human primate disease models. The ultimate goal is to
translate basic science into new therapeutic approaches
for patients suffering from neuropsychiatric or neurode-
generative conditions for which there are currently sub-
optimal or no treatment options.
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